Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratio

BACKGROUND: There remains a significant need to eliminate the risk of recurrence of resected cancers. Cancer vaccines are well tolerated and activate tumor-specific immune effectors and lead to long-term survival in some patients. We hypothesized that vaccination with alphaviral replicon particles e...

Descripción completa

Detalles Bibliográficos
Autores principales: Crosby, Erika J, Hobeika, Amy C, Niedzwiecki, Donna, Rushing, Christel, Hsu, David, Berglund, Peter, Smith, Jonathan, Osada, Takuya, Gwin III, William R, Hartman, Zachary C, Morse, Michael A, Lyerly, Herbert Kim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661359/
https://www.ncbi.nlm.nih.gov/pubmed/33177177
http://dx.doi.org/10.1136/jitc-2020-001662

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661359/
https://www.ncbi.nlm.nih.gov/pubmed/33177177
http://dx.doi.org/10.1136/jitc-2020-001662

Ejemplares similares